



# The Brazilian Journal of INFECTIOUS DISEASES

[www.elsevier.com/locate/bjid](http://www.elsevier.com/locate/bjid)



## Original article

# Coagulase-negative staphylococci: a 20-year study on the antimicrobial resistance profile of blood culture isolates from a teaching hospital



Valéria Cataneli Pereira <sup>a,b,\*</sup>, Letícia Calixto Romero <sup>a</sup>, Luiza Pinheiro-Hubinger <sup>a</sup>, Adilson Oliveira <sup>a</sup>, Katheryne Benini Martins <sup>a</sup>, Maria de Lourdes Ribeiro de Souza da Cunha <sup>a</sup>

<sup>a</sup> UNESP-Universidade Estadual Paulista, Instituto de Biociências de Botucatu, Departamento de Microbiologia e Imunologia, São Paulo, SP, Brazil

<sup>b</sup> UNOESTE-Universidade Oeste Paulista, Departamento de Microbiologia, São Paulo, SP, Brazil

## ARTICLE INFO

### Article history:

Received 4 September 2019

Accepted 27 January 2020

Available online 19 February 2020

### Keywords:

CoNS

MIC

Quinupristin/dalfopristin

SCCmec

Vancomycin

Tigecycline

Staphylococcus

## ABSTRACT

The increasing rates of nosocomial infection associated with coagulase-negative staphylococci (CoNS) were the rationale for this study, aiming to categorize oxacillin-resistant CoNS species recovered from blood culture specimens of inpatients at the UNESP Hospital das Clínicas in Botucatu, Brazil, over a 20-year period, and determine their sensitivity to other antimicrobial agents. The *mecA* gene was detected in 222 (74%) CoNS samples, and the four types of staphylococcal chromosomal cassette *mec* (SCCmec) were characterized in 19.4%, 3.6%, 54.5%, and 14.4% of specimens, respectively, for types I, II, III, and IV. Minimal inhibitory concentration (MIC) values to inhibit 50% (MIC<sub>50</sub>) and 90% (MIC<sub>90</sub>) of specimens were, respectively, 2 and >256 μL/mL for oxacillin, 1.5 and 2 μL/mL for vancomycin, 0.25 and 0.5 μL/mL for linezolid, 0.094 and 0.19 μL/mL for daptomycin, 0.19 and 0.5 μL/mL for quinupristin/dalfopristin, and 0.125 and 0.38 μL/mL for tigecycline. Resistance to oxacillin and tigecycline and intermediate resistance to quinupristin/dalfopristin were observed. Eight (2.7%) of all 300 CoNS specimens studied showed reduced susceptibility to vancomycin. Results from this study show high resistance rates of CoNS to antimicrobial agents, reflecting the necessity of using these drugs judiciously and controlling nosocomial dissemination of these pathogens.

© 2020 Sociedade Brasileira de Infectologia. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## Introduction

Coagulase-negative staphylococci (CoNS), members of the staphylococci group, are characterized as Gram-positive cocci,

presented as single cells or with irregular disposition, and are immobile, non-spore forming, catalase-positive, mostly facultative anaerobes, and lack the enzyme coagulase.<sup>1</sup> CoNS are part of the human microbiota, considered opportunistic pathogens, causing infections mostly in premature babies, and immunocompromised and prosthetic patients.<sup>2</sup>

\* Correspondence author.

E-mail address: [valeriacataneli@gmail.com](mailto:valeriacataneli@gmail.com) (V.C. Pereira).

<https://doi.org/10.1016/j.bjid.2020.01.003>

1413-8670/© 2020 Sociedade Brasileira de Infectologia. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

The rise of antimicrobial resistance in recent years has had a great impact on hospital infections caused by CoNS. Oxacillin is a semisynthetic penicillin used in the susceptibility test for the detection of methicillin resistance and treatment of staphylococcal infections. However, rates from 66% to 95% of oxacillin resistance have been observed in CoNS clinical isolates.<sup>2</sup> Oxacillin resistance is often mediated by the *mecA* gene, which encodes a supplemental penicillin-binding protein (PBP2a) with low-affinity to semisynthetic penicillins.<sup>3</sup> The *mecA* gene is located on a mobile genetic element known as the Staphylococcal Cassette Chromosome *mec* (SCC*mec*) which contains the *mec* complex, composed of the *mecA* gene and its regulator genes *mecI* and *mecR*, the *ccr* complex, responsible for integration and excision of the SCC*mec*, and J region, which is not essential for the SCC*mec* formation, but may carry non- $\beta$ -lactam resistance genes.<sup>4</sup> To date, 13 SCC*mec* types have been described, based on the combination of *ccr* gene complex types and *mec* gene complex classes. The subtypes were defined by J region polymorphisms in the same combination of *mec* and *ccr* complexes.<sup>5</sup>

The emergence of oxacillin resistant isolates has led to the ultimate use of alternative antimicrobials for treatment of CoNS infections, such as the glycopeptide vancomycin. In the meantime, descriptions of reduced susceptibility and resistance to vancomycin have been reported in recent decades.<sup>6</sup> Reduced susceptibility to vancomycin may be related to metabolic modifications such as acceleration in peptidoglycan synthesis, resulting in cell wall thickening. In this process, vancomycin is not able to inhibit the peptidoglycan synthesis, since it is depleted due to the higher availability of D-alanyl-D-alanine sites.<sup>7</sup>

Given the upsurge in hospital infections caused by CoNS, this study aimed to characterize the oxacillin resistant strains and determine the antimicrobial susceptibility of a 20-year collection of blood culture CoNS isolates from Botucatu Hospital das Clínicas inpatients.

## Material and methods

### Strains

Three-hundred CoNS strains were isolated from blood cultures from inpatients of the Botucatu Hospital das Clínicas – Paulista State University (UNESP). The isolates were collected from 1990 to 2009 and kept in the Culture Collection Laboratory of the Microbiology and Immunology Department of the Botucatu Biosciences Institute - UNESP. The selection criteria considered a mean prevalence of events of 35%, with a margin of error of 5%, and a 95% confidence interval.

The strains were isolated according to Koneman et al.<sup>8</sup> Blood-agar isolates were subjected to Gram stain for observation of colony morphology and the catalase test was performed for confirmation of the genus *Staphylococcus*. Staphylococcal strains were submitted to the coagulase test for differentiation of the coagulase-negative and coagulase-positive groups. Coagulase-negative isolates were subjected to biochemical tests for the phenotypic identification of species.

The genotypic identification was performed using primers drawn over conserved sequences adjacent to 16S and 23S genes, by ITS-PCR (*internal transcribed spacer–polymerase chain reaction*), described by Couto et al.<sup>9</sup> Amplification efficiency was monitored by electrophoresis in 3% metaphor agarose and stained with SYBR Safe. The following lineages of international reference were used: *S. auricularis* ATCC 33753, *S. capitis* subsp. *capitis* ATCC 27843, *S. capitis* subsp. *urealyticus* ATCC 49325, *S. caprae* ATCC 35538, *S. cohnii* ATCC 49330, *S. cohnii* subsp. *cohnii* ATCC 29974, *S. epidermidis* ATCC 12228, *S. epidermidis* ATCC 35983, *S. hemolyticus* ATCC 29970, *S. hominis* ATCC 27844, *S. hominis* subsp. *novobiosepticus* ATCC 700237, *S. lentus* ATCC 700403, *S. lugdunensis* ATCC 700328, *S. saprophyticus* ATCC 15305, *S. schleiferi* subsp. *schleiferi* ATCC 43808, *S. sciuri* subsp. *sciuri* ATCC 29062, *S. simulans* ATCC 27851, *S. xylosus* ATCC 29979, and *S. warneri* ATCC 10209.

### DNA extraction

The Illustra kit (GE Healthcare) was used for DNA extraction. The steps included an initial digestion of staphylococcal cells with lysozyme (10 mg/mL) and proteinase K (20 mg/mL). Next, 500  $\mu$ L of the extraction buffer were added to the mixture, which was centrifuged at 10,000 x g for 4 min. The supernatant was transferred to a column and centrifuged at 5,000g for 1 min. The fluid was discarded and 500  $\mu$ L of extraction buffer were added to the column. After the centrifugation and discarding of the collected fluid, 500  $\mu$ L of washing buffer were added to the column, which was submitted to centrifugation at 20,000g for 3 min. Next the column was transferred to a 1.5 mL tube and elution was performed using 200  $\mu$ L of warmed MilliQ water at 70 °C.

### The *mecA* gene detection

PCR was performed for the detection of the *mecA* gene. Reactions were performed using a protocol described by Murakami et al.<sup>10</sup> The amplification efficiency was monitored by electrophoresis in a 2% agarose gel stained with SYBR Safe.

### Determination of SCC*mec*

The SCC*mec* type was determined on *mecA*-positive strains. Reactions were performed using a protocol described by Oliveira et al.<sup>11</sup> and modified by Machado et al.<sup>12</sup>

Multiplex PCR was performed in 50  $\mu$ L of reaction volume with 1X enzyme buffer, 1.25 U Taq polymerase DNA, 200  $\mu$ M dNTP Mix, and the following primers: 10 pmol of R1fig2 fig2 (TTCGAGTTGCTGATGAAGAAGG) and C1F2 R2 (ATTTACCACAAGGACTACCAGC), 6 pmol of KDP F1 (AATCATCTGCCATTGGTGATGC) and KDP R1 (CGAATGAAGTGAAGAAAGTGG), 5 pmol of DCS F2 (CATCCTATGATAGCTTGGTC) and DSC R1 (CTAAATCATAGCCATGACCG), 5 pmol of R1fig4 fig3 (GTGATTGTTGAGATATGTGG), and RIF4 R9 (CGCTTTATCTGTATCTATCGC). For each reaction, 10  $\mu$ L DNA was added. The cycle sequencing reactions were performed at 92 °C for 3 min, followed by 30 cycles of 92 °C for 1 min, 56 °C for 1 min, and 72 °C for 1 min and 30 s. The amplification efficiency was mon-

itored by electrophoresis in a 2% agarose gel stained with SYBR Safe.

#### Determination of the minimal inhibitory concentration (MIC) by the E-test

The *in vitro* susceptibility of CoNS strains was tested for the following antimicrobials: Oxacillin, Vancomycin, Daptomycin, Linezolid, Quinupristin/Dalfopristin, and Tigecycline. The MIC of these drugs was determined by the E-test. The criteria used for the susceptibility classification were: Oxacillin <0.5 µg/mL (susceptible) for CoNS, except *S. lugdunensis* (susceptible ≤2 µg/mL and resistant ≥4 µg/mL); Vancomycin <4 µg/mL (susceptible), 8–16 µg/mL (intermediate resistant), and >32 µg/mL (resistant); Linezolid ≤4 µg/mL (susceptible); Daptomycin ≤1 µg/mL; Quinupristin/Dalfopristin ≤1 µg/mL (susceptible), 2 µg/mL (intermediate), and ≥4 µg/mL (resistant); Tigecycline ≤0.5 µg/mL.<sup>13</sup>

#### Screening test for the detection of reduced susceptibility to vancomycin

In order to detect reduced susceptibility to vancomycin, a screening agar test prepared with Brain Heart Infusion (BHI) Agar and 4 µg/mL, 6 µg/mL, 8 µg/mL, and 16 µg/mL of vancomycin was used. The reference strain *S. aureus* ATCC 29213, susceptible to vancomycin, was used as a negative control, and strain *E. faecalis* ATCC 51299, resistant to vancomycin, as a positive control. Spots of a 2.0 McFarland inoculum were added to the Agar plate and incubated at 35 °C for 24 h, and the growing of at least one colony was considered as a positive result.

#### Analysis of the cell wall thickness

The CoNS strains that presented reduced susceptibility to vancomycin were submitted to the transmission electronic microscopy for cell wall thickness analysis. Strains were cultured in BHI broth and incubated at 37° C for 24 h. In a microtube, 1000 µL of a CoNS culture broth were centrifuged for one minute at 12,000 rpm. After discarding the supernatant, strains were fixed in a Karnovsky solution (2.5% glutaraldehyde in phosphate buffer 0.1 M [pH 7.3]) for four hours. Samples were removed from the fixer and washed three times for five minutes in distilled water. Next the samples were immersed in 0.5% osmium tetroxide for 40 min, before being washed three times for 10 min in distilled water. Samples were dehydrated using increasing concentrations of alcohol: two times for 10 min in 7.5% alcohol; two times for 10 min in 15% alcohol; two times for 10 min in 30% alcohol; two times for 10 min in 50% alcohol; three times for 15 min in 70% alcohol; two times for 15 min in 90% alcohol; two times for 10 min in 100% alcohol. After the dehydration the stubs were mounted and samples metalized. The analyses were performed in an electronic microscopy Tecnai Spirit Fei Company and the images were obtained at a magnification of 30000×.

## Results

#### Identification of isolates

The identification of CoNS through the biochemical tests detected 223 (74.3%) *S. epidermidis*, 27 (9.0%) *S. hemolyticus*, 22 (7.3%) *S. hominis*, 14 (4.7%) *S. warneri*, 9 (3.0%) *S. lugdunensis*, and 5 (1.7%) *S. capitis*. Through the ITS-PCR method, 223 (74.3%)

**Table 1 – Origin of CoNS isolates and demographic data of patients with bacteremia at Hospital das Clínicas de Botucatu - Paulista State University between 1990 and 2009.**

Hospital ward	Genre (%)			Age (Average)	Coagulase-negative staphylococci species (%)						
	N	Female	Male		NA	<i>S. epidermidis</i> (N=223)	<i>S. hemolyticus</i> (N=29)	<i>S. hominis</i> (N=23)	<i>S. lugdunensis</i> (N=9)	<i>S. capitis</i> (N=5)	<i>S. warneri</i> (N=11)
Nursery/ NICU	157	67.9	32.6	58.3	9,9 days	57.4	37.9	39.1	55.6	0.0	36.4
Pediatrics/ PICU	25	5.7	12.4	0.0	8,5 months	8.1	10.3	8.7	11.1	0.0	9.1
Thoracic surgery	1	0.6	0.0	0.0	68 years old	0.4	0.0	0.0	0.0	0.0	0.0
Cardiology	4	1.9	0.8	0.0	56,3 years old	1.3	3.4	0.0	0.0	0.0	0.0
Internal medicine	10	2.5	4.7	0.0	57 years old	4.0	0.0	0.0	0.0	20.0	0.0
Dermatology	1	0.0	0.8	0.0	58 years old	0.0	0.0	0.0	0.0	0.0	9.1
Dialysis	8	2.5	3.1	0.0	24 years old	3.1	3.4	0.0	0.0	0.0	0.0
Gastroenterology	5	0.0	3.9	0.0	57 years old	0.4	3.4	0.0	22.2	20.0	0.0
Obstetrics and gynecology	1	0.6	0.0	0.0	73 years old	0.0	3.4	0.0	0.0	0.0	0.0
Infectious Diseases	3	0.0	2.3	0.0	16 years old	1.3	0.0	0.0	0.0	0.0	0.0
Nephrology	6	1.9	2.3	0.0	52 years old	1.8	6.9	0.0	0.0	0.0	0.0
Neurology	7	1.3	3.9	0.0	39,6 years old	0.9	3.4	8.7	0.0	40.0	0.0
Orthopedics	1	0.0	0.8	0.0	NA	0.0	0.0	0.0	0.0	0.0	9.1
Emergency Room	42	8.8	21.7	0.0	58,1 years old	11.7	20.7	30.4	0.0	20.0	18.2
ICU	22	5.0	10.1	8.3	58.5 years old	7.6	6.9	13.0	0.0	0.0	0.0
NA	7	1.3	0.8	33.3	42 years old	1.8	0.0	0.0	11.1	0.0	18.2

N, number; NICU, neonatal intensive care unit; PICU, pediatrics intensive care unit; ICU, intensive care unit; NA, not available.

*S. epidermidis*, 29 (9.7%) *S. hemolyticus*, 23 (7.7%) *S. hominis*, 11 (3.7%) *S. warneri*, 9 (3.0%) *S. lugdunensis*, and 5 (1.7%) *S. capitis* were detected. Agreement between the identification methods was found in 98% of cases.

Table 1 presents the source of the CoNS species isolates, as well as the demographic data of the patients with bacteremia.

#### Detection of *mecA* gene and characterization of SCCmec

The *mecA* gene was detected in 222 (74%) of the studied samples, found in 78.5% of *S. epidermidis*, 75.9% of *S. hemolyticus*, 69.6% of *S. hominis*, 27.3% of *S. warneri*, 80% of *S. capitis*, and 22.2% of *S. lugdunensis*.

The characterization of SCCmec in *mecA*-positive strains was as follows: 43 (19.4%) were classified as type I, 8 (3.6%) as type II, 121 (54.5%) as type III, 32 (14.4%) as type IV, and 18 (8.1%) were not typed by this method. The correlations between the SCCmec types and methicillin-resistant CoNS species are presented in Table 2.

#### Determination of the minimal inhibitory concentration (MIC)

The MICs of the antimicrobials used for the treatment of CoNS infections was determined by the E-test. Oxacillin resistance was found in 206 (68.7%) CoNS strains and 25 were tigecycline resistant (8.3%). Resistance to tigecycline was detected in 4.5% of *S. epidermidis*, 13.8% of *S. hemolyticus*, 13% of *S. hominis*, and 11.1% of *S. lugdunensis*. For quinupristin/dalfopristin, one *S. epidermidis* isolate presented intermediate resistance with an MIC of 2 µg/mL, and one *S. epidermidis* and one *S. hemolyticus* with MICs of 3 µg/mL. The sensitivity and specificity of the oxacillin MIC by the E-test compared with the presence of *mecA* were, respectively, 87.4% and 82.3%.

The antimicrobial MICs for inhibition of 50% and 90% of strains (MIC<sub>50</sub> and MIC<sub>90</sub>) were, respectively, 2 µL/mL and >256 µL/mL for oxacillin, 1.5 µL/mL and 2 µL/mL for vancomycin, 0.25 µL/mL and 0.5 µL/mL for linezolid, 0.094 µL/mL and 0.19 µL/mL for daptomycin, 0.19 µL/mL and 0.5 µL/mL for quinupristin/dalfopristin, and 0.125 µL/mL and 0.38 µL/mL for tigecycline.

With respect to CoNS species, the parameter distribution of MIC<sub>50</sub> and MIC<sub>90</sub> revealed high rates of oxacillin resistance in *S. hemolyticus*. This was the only CoNS species for which the minimal concentration to inhibit 50% of isolates was >256 µg/mL, reflecting the high resistance rate of *S. hemolyticus* to oxacillin (Table 3).

The MIC range of each antimicrobial was compared to the SCCmec type. The isolates typed as SCCmecI presented higher tigecycline MICs and those classified as SCCmecII presented the highest oxacillin MICs. The SCCmecIV strains showed the highest MIC values for vancomycin, linezolid, daptomycin, and quinupristin/dalfopristin (Table 4).

An evaluation was performed of the oxacillin and vancomycin MICs over a period of 20 years, divided into three time periods according to the distribution of oxacillin and vancomycin MIC ranges. For oxacillin, in the first period (1990–2001), higher values of MIC were observed, but still indicating susceptibility. In the other periods (2002–2006 and 2007–2009), a decrease in the MIC val-

ues was observed, still indicating susceptibility, as well as an increase in the resistance rates. Regarding vancomycin, the same evaluation demonstrated significant differences in the three periods among strains with MICs from 0.047 µg/mL to 0.38 µg/mL and from 0.5 µg/mL to 2.0 µg/mL (Fig. 1).

#### Determination of the reduced susceptibility to vancomycin

A growth of 214 (71.3%) strains was observed on the BHI plate with 4 µg/mL of vancomycin, 89 (29.7%) on the plate with 6 µg/mL of vancomycin, and 8 (2.6%) isolates on the 8 µg/mL vancomycin plate. None of the isolates grew in the medium with 16 µg/mL of vancomycin. There were no significant differences in MICs between strains that presented no growth on the plate complemented with vancomycin and those which grew on the 4 µg/mL vancomycin plate. Among those that showed growth on the medium with 6 µg/mL of vancomycin, the MIC range was 0.5–2 µg/mL. Among those which grew on 8 µg/mL of vancomycin, the MIC range was 0.75–24 µg/mL. The strains grown on 8 µg/mL of vancomycin were four *S. epidermidis*, one *S. hemolyticus*, two *S. hominis*, and one *S. capitis*, all resistant to oxacillin, and *S. epidermidis* and *S. capitis* being carriers of SCCmec III, *S. hominis* of SCCmec I, and *S. hemolyticus* with non-typed SCCmec.

#### Analysis of the cell wall thickness of strains with reduced susceptibility to vancomycin

The cell wall thickness under cell division was measured in eight strains (values are presented in nanometers, mean ± SD). The four *S. epidermidis* strains presented mean values of 21.66 ± 1.4, 20.12 ± 0.9, 24.24 ± 1.3, and 14.20 ± 1.3 nm. The *S. hemolyticus* isolate showed a cell wall thickness of 24.88 ± 1.7 nm. For the *S. capitis* isolate, the cell wall thickness was 19.33 ± 1.8, and for the two *S. hominis* isolates the values were 17.68 ± 2.1 and 24.92 ± 1.5. For comparison, the used reference strains *S. epidermidis* ATCC 12228 and *S. hemolyticus* ATCC29970 showed cell wall thicknesses of, respectively, 14.61 ± 1.2 and 14.73 ± 0.7 nm. The comparison of the studied strains against controls showed higher values, ranging from 17 nm to 24.92 nm, with the exception of one *S. epidermidis* isolate, which presented a lower value compared to the controls (Fig. 2).

#### CoNS bacteremia evolution

The possible evolution of bacteremia to other infections, such as sepsis, pneumonia, urinary tract infection, meningitis, peritonitis, necrotizing enterocolitis, omphalitis, and brain abscess, was followed up in 52 patients admitted to the neonatal wards. Of these, in 25 (46.3%) patients the same CoNS isolated from blood culture was confirmed to be the etiologic agent of infection. In six (11.1%), CoNS was the possible agent of infection, and in 23 (42.6%) CoNS was not related to the patient's infection (Fig. 3).

The *mecA* gene was detected in 33 (61.1%) of these CoNS, with 20 (60.6%) CoNS associated with more severe infections or possible agents of these infections.

**Table 2 – Classification of SCCmec types among the methicillin-resistant CoNS species.**

	mecA (+)		SCCmec									
	N	%	Type I		Type II		Type III		Type IV		Non-typed	
			N	%	N	%	N	%	N	%	N	%
<i>S. epidermidis</i> (223)	175	78.5	28	16.0	2	1.1	108	61.7	32	18.3	5	2.9
<i>S. hemolyticus</i> (29)	22	75.9	6	27.3	6	27.3	4	18.2	0	0.0	6	27.3
<i>S. hominis</i> (23)	16	69.6	8	50.0	0	0.0	5	31.3	0	0.0	3	18.8
<i>S. warneri</i> (11)	3	27.3	0	0.0	0	0.0	0	0.0	0	0.0	3	100
<i>S. capitis</i> (5)	4	80.0	1	25.0	0	0.0	2	50.0	0	0.0	1	25.0
<i>S. lugdunensis</i> (9)	2	22.2	0	0.0	0	0.0	2	100	0	0.0	0	0.0
N Total	223		43		8		121		32		18	

N, number of samples.

**Table 3 – Determination of MIC<sub>50</sub>, MIC<sub>90</sub>, MIC range (µg/ml), and antimicrobial resistance in CoNS species.**

Species	Antimicrobial	MIC <sub>50</sub>	MIC <sub>90</sub>	MIC range	% Resistance
<i>S. epidermidis</i> (223)	Oxacillin	2	>256	0.047 ≥ 256	73.5
	Vancomycin	1.5	2	0.125–2	0
	Linezolid	0.25	0.5	0.047–2	0
	Daptomycin	0.094	0.19	0.016–0.75	0
	Quinupristin/Dalfopristin	0.19	0.38	0.064–3	0
	Tigecycline	0.094	0.38	0.016–1.5	6.7
	Oxacillin	>256	>256	0.064 ≥ 256	79.3
<i>S. hemolyticus</i> (29)	Vancomycin	1	1.5	0.19–2	0
	Linezolid	0.25	0.5	0.094 ± 1	0
	Daptomycin	0.064	0.125	0.016–0.19	0
	Quinupristin/Dalfopristin	0.25	0.5	0.025–1	0
	Tigecycline	0.25	0.5	0.016–2	17.2
	Oxacillin	0.75	>256	0.019 ≥ 256	56.5
	Vancomycin	0.75	2	0.125–2	0
<i>S. hominis</i> (23)	Linezolid	0.25	0.5	0.064–0.75	0
	Daptomycin	0.047	0.064	0.023–0.094	0
	Quinupristin/Dalfopristin	0.25	0.38	0.125–0.38	0
	Tigecycline	0.094	0.5	0.016–0.75	13
	Oxacillin	0.19	0.38	0.19–0.38	0
	Vancomycin	0.5	1.5	0.25–1.5	0
	Linezolid	0.25	0.5	0.125–0.75	0
<i>S. warneri</i> (11)	Daptomycin	0.125	0.25	0.047–0.32	0
	Quinupristin/Dalfopristin	0.25	0.38	0.125–0.38	0
	Tigecycline	0.094	0.38	0.047–0.64	9
	Oxacillin	0.38	>256	0.19 ≥ 256	38.2
	Vancomycin	0.75	1.5	0.38–2	0
	Linezolid	0.25	0.5	0.19–2	0
	Daptomycin	0.064	0.064	0.023–0.094	0
<i>S. lugdunensis</i> (9)	Quinupristin/Dalfopristin	0.19	0.25	0.125–1.5	0
	Tigecycline	0.047	0.25	0.032–1	11.1
	Oxacillin	1	3	0.19–3	80
	Vancomycin	1.5	1.5	0.38–1.5	0
	Linezolid	0.38	0.5	0.25–0.5	0
	Daptomycin	0.25	0.38	0.016–0.38	0
	Quinupristin/Dalfopristin	0.5	1.5	0.19–1.5	0
<i>S. capitis</i> (5)	Tigecycline	0.125	0.25	0.064–0.25	0

MIC, Minimal Inhibitory Concentration. MIC<sub>50</sub>, Minimal Concentration necessary to inhibit 50% of bacterial growth. MIC<sub>90</sub>, Minimal Concentration necessary to inhibit 90% of bacterial growth.

## Discussion

The CoNS are considered one of the main causes of bacteremia. The importance of these bacteria has increased in the hospital environment during recent years, mostly due to

antimicrobial resistance. In the present work, 300 CoNS strains isolated from blood cultures of inpatients at the Hospital of Clinics of Botucatu, over a period of 20 years, were studied. These isolates were characterized regarding their antimicrobial susceptibility.

Antimicrobial	MIC range (µg/ml)			
	SCCmec I	SCCmec II	SCCmec III	SCCmec IV
Oxacillin	0.094 ≥ 256	6 ≥ 256	0.125 ≥ 256	0.125 ≥ 256
Vancomycin	0.25-2	0.38-2	0.125-2	0.75-2
Linezolid	0.064-1	0.19-0.5	0.047-0.75	0.064-1
Daptomycin	0.016-0.25	0.016-0.094	0.019-0.5	0.047-0.75
Quinupristin/Dalfopristin	0.025-1.5	0.094-0.5	0.064-1	0.125-2
Tigecycline	0.016-2	0.023-0.75	0.016-0.75	0.032-1

MIC, Minimal Inhibitory Concentration.




Fig. 1 – Correlation between the number of CoNS and oxacillin and vancomycin MICs in the three periods: 1990-2001; 2002-2006; 2007-2009.





Fig. 2 – Transmission Electronic Microscopy images of CoNS under division, for observation of cell wall thickness (in nanometers).

a) *S. hominis* b) *S. epidermidis* ATCC 12228.

The *mecA* detection determined oxacillin resistance in 78.5% of CoNS, and the MIC<sub>50</sub> value (2 µg/mL) was indicative of resistance to this drug, confirming the low susceptibility of these bacteria to β-lactam agents. Previous works have demonstrated that since the 1970s the CoNS isolates have presented higher oxacillin resistance rates than *S. aureus*.<sup>14,15</sup> The β-lactam resistance rates have been shown to range from

65% to 95% in hospitals in Brazil and in other countries.<sup>2,16,17</sup> The highest rates of oxacillin resistance were found in *S. epidermidis*, followed by *S. hemolyticus*, *S. hominis*, and *S. capitis*. Similar results were described in previous studies, which showed oxacillin resistance in 97% of *S. epidermidis* between 1999 and 2001 in a neonatal intensive care unit (NICU),<sup>18</sup> in 96% of *S. hemolyticus* isolated in Brazil,<sup>19</sup> and in 100% of *S.*



**Fig. 3 – Correlation of CoNS isolated from blood cultures as possible etiologic agents of infections caused in neonatal unit patients.**

*hominis* isolated in an NICU from Spain.<sup>20</sup> Regarding *S. capitis*, discrepant results were found in the studies conducted by Caierão et al.<sup>21</sup>

Although at a lower frequency, the *mecA* gene was detected in *S. warneri* and *S. lugdunensis*. *S. warneri* has been described with rates of 33.3% of oxacillin resistance in NICUs,<sup>22</sup> and the first description of *mecA* in *S. lugdunensis* was in the study conducted by Kawaguchi et al.<sup>23</sup> Despite the low resistance rates,<sup>24</sup> determination of antimicrobial susceptibility of *S. lugdunensis* is important, not only due to its clinical implications, since this species is the most aggressive of the CoNS, but also for the establishment of early treatment with adequate antimicrobials and good clinical results.<sup>25</sup>

The characterization of the SCCmec showed the presence of types I-IV in the isolates, with SCCmecIII being the most frequently detected in the studied strains, mainly in *S. epidermidis*, the only species that carried type IV. SCCmec type III is the largest of them all, codifies for several resistance-associated genes, and is the most commonly isolated CoNS from hospital specimens. *S. epidermidis* is the main colonizer of the human skin and the most commonly detected in infection sites. The selective pressure in the hospital environment leads to dissemination of SCCmec III strains, which are associated with serious infections.<sup>26</sup> SCCmec type IV has been related with community-associated *Staphylococcus* spp., and was described for the first time in an *S. epidermidis* strain, a fact that implies its transference from *S. epidermidis* to *S. aureus*. A reduced cost transfer of SCCmec IV due to its small size would probably lead to a higher incidence of infections caused by SCCmec IV carriers.<sup>12,27</sup> SCCmecII presented an association with *S. hemolyticus*, similar to the findings of Machado et al.,<sup>12</sup> whose work only detected type II in this species.

The alternative for the treatment of oxacillin resistant staphylococci is vancomycin, a glycopeptide first used in 1958 in invasive infections. There are, however, descriptions of resistance and reduced susceptibility to this drug,<sup>6</sup> although unstable.<sup>28</sup> The results of the current work showed that, with the exception of oxacillin, vancomycin was the drug with the highest values of MIC<sub>50</sub> and MIC<sub>90</sub>. Despite the full susceptibility of the collection, the MIC values were the highest in the period of 20 years, and reduced susceptibility was detected

in some *S. epidermidis*, *S. hemolyticus*, *S. hominis*, and *S. capitis* strains. In the studies performed by Natoli et al.,<sup>29</sup> reduced susceptibility to vancomycin was detected with a frequency of 5.4% among CoNS isolates, in *S. epidermidis* and *S. hemolyticus* species. According to the same authors, *Staphylococcus* colonies grown on vancomycin agar may lead to glycopeptide heteroresistance, which can be a precursor of glycopeptide resistance, causing complicated infections and treatment failure. This should be taken into consideration in therapeutic decisions.<sup>30</sup>

The increase in the proportion of oxacillin resistant CoNS and decrease in their susceptibility to vancomycin emphasize the importance of studies involving other therapeutic choices. Tigecycline, a Gram-positive and negative broad spectrum semisynthetic glycycline, is considered a drug with excellent activity against oxacillin susceptible and resistant CoNS,<sup>14,29</sup> despite our data showing rates of 8.3% of resistance, most often in *S. hemolyticus*, followed by *S. hominis*, *S. lugdunensis*, and *S. epidermidis*. Similar MIC<sub>90</sub> results were described for tigecycline, with no difference between oxacillin resistant and susceptible CoNS.<sup>31</sup> In the studies conducted by Natoli et al.<sup>29</sup> tigecycline demonstrated good activity against CoNS. According to those authors, tigecycline is not recommended for the treatment of bacteremia and its use should be limited in order to preserve activity against multi-resistant Gram-negative bacteria. Mutations in the ribosomal gene S10 and *rpsJ* and *mepA* genes seem to be associated with tigecycline resistance.<sup>32,33</sup>

Quinupristin/dalfopristin is a streptogramin belonging to the macrolide-lincosamide-streptogramin group. The combination of quinupristin and dalfopristin is synergistic and usually bactericidal when these agents are compared singly, or compared to similar macrolide antimicrobials.<sup>34</sup> In this work, despite presenting excellent efficacy in the majority of the studied CoNS, intermediate resistance to this drug was detected in two *S. epidermidis* and one *S. hemolyticus*. In the study conducted by Mendes et al.,<sup>35</sup> quinupristin/dalfopristin demonstrated excellent effectiveness for CoNS, the strains were fully susceptible, with MIC<sub>90</sub> values of 0.38 µg/mL for the oxacillin-susceptible strains and 0.75 µg/mL for the oxacillin resistant strains. In addition, Venkatesh et al.<sup>36</sup> described good effectiveness of quinupristin/dalfopristin for oxacillin resistant and susceptible strains.

Daptomycin, an antimicrobial studied for decades, was brought back into use in 2006, for the treatment of bacteremia and endocarditis caused by *Staphylococcus*.<sup>37</sup> In the present study, daptomycin showed excellent efficacy for CoNS isolates, with low MIC<sub>50</sub> values. Olivares et al.<sup>37</sup> also verified the susceptibility of all CoNS to daptomycin, with low variation in the MIC values. In a work studying 1126 CoNS, conducted by Critchley et al.,<sup>38</sup> daptomycin was active on a MIC range from 0.015 to 2.0 µg/mL, and the MIC<sub>90</sub> was 0.5 µg/mL. According to those authors, the most active agents in these analyses were daptomycin and quinupristin/dalfopristin, which emphasizes the relevance of these antimicrobials in the treatment of infections caused by CoNS.

Linezolid, a synthetic oxazolidinone potentially active against several bacteria, is another drug that has demonstrated good efficacy against CoNS.<sup>39</sup> Linezolid has become important for the therapeutic treatment of chronic infections

by CoNS, despite the description of resistance. In Brazil, the first case of linezolid resistance was described in 2006, on a clinical isolate of MRSA<sup>40</sup> and, among the CoNS, in *S. epidermidis*, *S. hominis*, and *S. hemolyticus*.<sup>41</sup> In the work conducted by Olivares et al.,<sup>37</sup> despite the detection of seven linezolid resistant strains, this drug presented effective MIC values in CoNS strains. On the other hand, an outbreak of linezolid resistant *S. epidermidis* clones containing mutations in ribosomal proteins L3 and L4, as well as the *cfr* plasmid, recently identified in France, have been reported.<sup>42</sup>

*S. hemolyticus* was the species that presented the highest oxacillin MIC values, and concentrations higher than 256 µg/mL were needed to inhibit 50% of isolates. As well as for oxacillin, this species presented higher MIC values for tigecycline and most of the antimicrobials tested. Several works show high rates of resistance to the antimicrobials used for the treatment of infections caused by *S. hemolyticus*, especially methicillin and glycopeptides. Some authors describe a high prevalence of genes encoding resistance to β-lactam and aminoglycoside agents, as well as a significant proportion of isolates with MIC values close to the resistance breakpoint,<sup>43,44</sup> emphasizing the importance of *S. hemolyticus* as a multiresistant pathogen.

The association of the MIC range with the SCCmec types demonstrated higher MICs for vancomycin, linezolid, daptomycin, and quinupristin/dalfopristin in *S. epidermidis* carrying SCCmecIV. The genes related to resistance to these antimicrobials are mediated by plasmids, found mostly in methicillin resistant strains with hospital origin.<sup>45</sup> SCCmec IV is characteristic of community isolates, especially due to its size and low adaptive cost. Studies suggest that the acquisition of resistance genes has environmental non-clinical origin, given the high diversity of resistance gene carriers in the natural environment.<sup>46,47</sup> Furthermore, SCCmecIV was only detected in *S. epidermidis*, which as the most common species in human skin is the most influenced by selective pressure. The higher MICs compared to other antimicrobials may also be related to the selective pressure, as the level of exposure to these drugs in the hospital environment would bias the selection of reduced susceptibility and resistant strains, since several mutation events, genetic recombination, and modifications in the microbial physiology are needed to generate phenotypic changes.<sup>48</sup>

Metabolic and physiological modifications related to selective pressure could be observed in strains grown on 8 µg/mL vancomycin agar, as the cell wall thickening was found in most CoNS isolates due to increased peptidoglycan synthesis. This mechanism is more advantageous for CoNS than the acquisition of the *van* operon, which is a mediator of vancomycin resistance. The *van* operon is acquired by horizontal gene transfer and its expression is only stimulated in the presence of glycopeptide. This stimulus causes a very high adaptive cost in the presence of vancomycin, being disadvantageous for the CoNS in a vancomycin medium.<sup>48,49</sup> Regarding the acquisition of other resistance genes in CoNS, such as the *mecA* gene, the initial adaptive cost is softened by compensatory additional mutations for the resistance “costs”. Recently, punctual mutations in genes such as *vraR* have been shown to be associated with reduced susceptibility to vancomycin and cell wall thickening in staphylococci.<sup>50</sup>

The present study showed a high rate of bacteremia caused by CoNS in neonatal and pediatric units, involving children under one year of age, the main agents being *S. epidermidis*, *S. hemolyticus*, *S. hominis*, *S. lugdunensis*, and *S. warneri*. *S. capitis* were not isolated in these units, being agents of bacteremia in adults admitted to the internal medicine ward, gastroenterology, neurology, and emergency room.

As the study involved bacteremia caused by staphylococci isolated over more than 30 years, much of the data associated with patients' medical records could not be retrieved, so it was not possible to associate the infection outcome of all patients, which is a limitation of the current study. Data obtained from patients in neonatal units indicated the clinical importance of CoNS bacteremia, which may progress to diseases that require specialized care.

Knowledge of antimicrobial resistance is of great importance for the correct treatment of infections caused by CoNS. Furthermore, the virulence factors of these bacteria and the immunity of patients are factors that contribute to the ability of the microorganism to cause more serious infections.

The results of our study spanning 20 years showed a high frequency of antimicrobial resistance in CoNS, which reflects the excessive use of these drugs. Besides the metabolic and physiologic modifications that could lead to reduced susceptibility to antimicrobials, their condition as human commensal bacteria make them ideal transporters and an efficient reservoir of resistance genes, especially the low-cost elements, such as SCCmec.<sup>45</sup> The antimicrobials which offered the best results should be used in such a way as to preserve their efficacy and prevent resistance.

---

## Conflicts of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

---

## Acknowledgments

We thank the São Paulo Research Foundation (FAPESP- Process: 2011/23742-2) and the National Council for Scientific and Technological Development (CNPq- Process: 470649/2011-9) for the financial support.

---

## REFERENCES

- Garrity GM, Labeda DP, Oren A. Judicial Commission of the International Committee on Systematics of Prokaryotes \* XIIth International (IUMS) Congress of Bacteriology and Applied Microbiology: minutes of the meetings, 3, 4 and 6 August 2008, Istanbul, Turkey. *Int J Syst Evol Microbiol*. 2011;61:2775–80.
- Rocchetti TT, Martins KB, Martins PYF, et al. Detection of the *mecA* gene and identification of *Staphylococcus* directly from blood culture bottles by multiplex polymerase chain reaction. *Brazilian J Infect Dis*. 2018;22:99–105.
- Archer GL, Niemeyer DM. Origin and evolution of DNA associated with resistance to methicillin in staphylococci. *Trends Microbiol*. 1994;2:343–7.



4. Ito T, Katayama Y, Asada K, Mori N, Tsutsumimoto K. Structural comparison of three types of staphylococcal cassette chromosome mec integrated in the chromosome in methicillin-resistant *Staphylococcus aureus*. *Antimicrob Agents Chemother*. 2001;45:1323-36.
5. Wu Z, Li F, Liu D, Xue H, Zhao X. Novel type XII staphylococcal cassette chromosome mec harboring a new cassette chromosome recombinase, CcrC2. *Antimicrob Agents Chemother*. 2015;59:7597-601.
6. Palazzo ICV, Araujo MLC, Darinia LC. First report of vancomycin-resistant staphylococci isolated from healthy carriers in Brazil. *J Clin Microbiol*. 2005;43:179-85.
7. Appelbaum PC. The emergence of vancomycin-intermediate and vancomycin-resistant *Staphylococcus aureus*; 2006. p. 256.
8. Koneman EW, Allen SD, Janda WM, Schreckenberger PC. *W C W. Color Atlas and Textbook of Diagnostic Microbiology*. 5th ed. Philadelphia: Lippincott; 1997.
9. Couto I, Pereira S, Miragaia M, Santos Sanches I, De Lencastre H. Identification of clinical staphylococcal isolates from humans by internal transcribed spacer PCR. *J Clin Microbiol*. 2001;39:3099-103.
10. Murakami K, Minamide W, Wada K, Nakamura E, Teraoka H, Watanabe S. Identification of methicillin-resistant strains of staphylococci by polymerase chain reaction. *J Clin Microbiol*. 1991;29:2240-4. Doi: 1939577.
11. Oliveira DC. Multiplex PCR Strategy for Rapid Identification of Structural Types and Variants of the Society. *Antimicrob Agents Chemother*. 2002;46:2155-61.
12. Machado ABMP, Reiter KC, Paiva RM, Barth AL. Distribution of staphylococcal cassette chromosome mec (SCCmec) types I, II, III and IV in coagulase-negative staphylococci from patients attending a tertiary hospital in southern Brazil. *J Med Microbiol*. 2007;56:1328-33.
13. (CLSI) Clinical and Laboratory Standards. Performance standards for antimicrobial susceptibility testing, document M100-S23. 2016.
14. John JF, Harvin AM. History and evolution of antibiotic resistance in coagulase-negative staphylococci: susceptibility profiles of new anti-staphylococcal agents. *Ther Clin Risk Manag*. 2007;3:1143-52.
15. Becker K, Heilmann C, Peters G. Coagulase-negative staphylococci. *Clin Microbiol Rev*. 2014;27:870-926.
16. Bouchami O, Achour W, Mekni MA, Rolo J, Ben Hassen A. Antibiotic resistance and molecular characterization of clinical isolates of methicillin-resistant coagulase-negative staphylococci isolated from bacteremic patients in oncohematology. *Folia Microbiol (Praha)*. 2011;56:122-30.
17. Martins A, Moraes Riboli DF, Cataneli Pereira V, et al. Molecular characterization of methicillin-resistant *Staphylococcus aureus* isolated from a Brazilian university hospital. *Braz J Infect Dis*. 2014;3-7.
18. Krediet TG, Mascini EM, Rooij E Van, Vlooswijk J, Paauw A, Gerards LJ. Molecular epidemiology of coagulase-negative staphylococci causing sepsis in a neonatal intensive care unit over an 11-year period. *J Clin Microbiol*. 2004;42:992-5, <http://dx.doi.org/10.1128/JCM.42.3.992>.
19. Ferreira RBR, Iorio NLP, Malvar KL, et al. Coagulase-negative staphylococci : comparison of phenotypic and genotypic oxacillin susceptibility tests and evaluation of the agar screening test by using different concentrations of oxacillin. *J Clin Microbiol*. 2003;41:3609-14.
20. Chaves F, García-Alvarez M, Sanz F, Alba C, Otero JR. Nosocomial spread of a *Staphylococcus hominis* subsp. novobiosepticus strain causing sepsis in a neonatal intensive care unit. *J Clin Microbiol*. 2005;43:4877-9.
21. Caierão J, Muszkopf M, Superti S, Roesch E, Dias CG, d'Azevedo PA. Evaluation of phenotypic methods for methicillin resistance characterization in coagulase-negative staphylococci (CNS). *J Med Microbiol*. 2004;53:1195-9.
22. Giusti MDe, Pacifico L, Panero A, Boccia A, Chiesa C. Phenotypic detection of nosocomial; 1999. p. 351-8.
23. Kawaguchi EW, Minamide HM, Igmi H. The taxonomic distribution, characteristic and susceptibility against antimicrobial agents of methicillin-resistant staphylococci isolated from blood. *Kansenshogaku Zasshi*. 1996;70:1147-53.
24. Mchardy IH, Veltman J, Hindler J, Bruxvoort K, Carvalho MM, Humphries RM. Clinical and microbiological aspects of  $\beta$ -lactam resistance in *Staphylococcus lugdunensis*. *J Clin Microbiol*. 2017;55:585-95.
25. Tee WSN, Yen Soh S, Lin R, Loo LH. *Staphylococcus lugdunensis* carrying the *mecA* gene causes catheter-associated bloodstream infection in premature neonate. *J Clin Microbiol*. 2003;41:519-20.
26. Ito T, Katayama Y, Hiramatsu K. Cloning and nucleotide sequence determination of the entire *mec* DNA of pre-methicillin-resistant *Staphylococcus aureus* N315. *Antimicrob Agents Chemother*. 1999;43:1449-58.
27. Healy CM, Hulten KG, Palazzi DL, Campbell JR, Baker CJ. Emergence of new strains of methicillin-resistant *Staphylococcus aureus* in a neonatal intensive care unit. *Clin Infect Dis*. 2004;39:1460-6.
28. Mashaly GES, El-Mahdy RH. Vancomycin heteroresistance in coagulase negative *Staphylococcus* blood stream infections from patients of intensive care units in Mansoura University Hospitals, Egypt. *Ann Clin Microbiol Antimicrob*. 2017;16:3-7.
29. Natoli S, Fontana C, Favaro M, et al. Characterization of coagulase-negative staphylococcal isolates from blood with reduced susceptibility to glycopeptides and therapeutic options. *BMC Infect Dis*. 2009;9:83.
30. Sullivan SB, Austin ED, Stump S, et al. Reduced vancomycin susceptibility of methicillin-susceptible *Staphylococcus aureus*: no significant impact on mortality but increase in complicated infection. *Antimicrob Agents Chemother*. 2017;61, <http://dx.doi.org/10.1128/AAC.00316-17>. AAC.00316-17.
31. Noskin GA. Tigecycline: a new glycycline for treatment of serious infections. *ClinInfectDis*. 2005;41:S303-14 (1537-6591 (Electronic)).
32. Angeles Argudin M, Roisin S, Dodémont M, Nonhoff C, Deplano A, Denisa O. Mutations at the ribosomal *s10* gene in clinical strains of *Staphylococcus aureus* with reduced susceptibility to tigecycline. *Antimicrob Agents Chemother*. 2018;62:2017-9.
33. Haim MS, Di Gregorio S, Galanternik L, et al. First description of *rpsJ* and *mepA* mutations associated with tigecycline resistance in *Staphylococcus aureus* isolated from a cystic fibrosis patient during antibiotic therapy. *Int J Antimicrob Agents*. 2017;50:739-41.
34. Manzella JP. Quinupristin-dalfopristin: a new antibiotic for severe gram-positive infections. *Am Fam Physician*. 2001;64:1863-6.
35. Mendes C, Sinto SI, Hsiung A, et al. Atividade antimicrobiana in vitro de quinupristina/dalfopristina para cocos gram-positivos isolados de cinco centros brasileiros: resultado do estudo de vigilância L-SMART. *J Bras Patol Med Lab*. 2002;38, <http://dx.doi.org/10.1590/S1676-24442002000300005>.
36. Venkatesh MP, Placencia F, Weisman LE. Coagulase-negative staphylococcal infections in the neonate and child: an update. *Semin Pediatr Infect Dis*. 2006;17:120-7.
37. Fajardo Olivares M, Hidalgo Orozco R, Rodríguez Garrido S, Rodríguez-Vidigal FF, Vera Tomé A, Robles Marcos M. Activity of vancomycin, ciprofloxacin, daptomycin, and linezolid against coagulase-negative staphylococci bacteremia. *Rev Esp Quimioter*. 2011;24:74-8.

38. Critchley IA, Blosser-middleton S, Jones ME, Thornsberry C, Sahm DF, Karlowsky JA. Baseline study to determine in vitro activities of daptomycin against gram-positive pathogens isolated in the United States in 2000-2001. *Antimicrob Agents Chemother.* 2003;47:1689-93.
39. de Almeida LM. Caracterização molecular dos mecanismos de resistência à linezolida em estafilococos coagulase-negativos e estudo da estabilidade do fenótipo resistente. Universidade de São Paulo; 2012.
40. Gales A, Sader H, Andrade S, Lutz L, Machado A, Barth A. Emergence of linezolid-resistant *Staphylococcus aureus* during treatment of pulmonary infection in a patient with cystic fibrosis. *Int J Antimicrob Agents.* 2006;27:300-2.
41. Lincopan N, de Almeida LM, Elmor de Araújo MR, Mamizuka EM. Linezolid resistance in *Staphylococcus epidermidis* associated with a G2603T mutation in the 23S rRNA gene. *Int J Antimicrob Agents.* 2009;34:281-2.
42. Dortet L, Glaser P, Kassis-Chikhani N, et al. Long-lasting successful dissemination of resistance to oxazolidinones in MDR *Staphylococcus epidermidis* clinical isolates in a tertiary care hospital in France. *J Antimicrob Chemother.* 2018;73:41-51.
43. Fredheim EGA, Klingenberg C, Rohde H, et al. Biofilm formation by *staphylococcus haemolyticus*. *J Clin Microbiol.* 2009;47:1172-80.
44. Frogatt JW, Johnston JL, Galetto DW, Archer GL. Antimicrobial resistance in nosocomial isolates of {*Staphylococcus haemolyticus*}. *Antimicrob Agents Chemother.* 1989;33:460-6.
45. Otto M. *Staphylococcus epidermidis*—the “accidental” pathogen. *Nat Rev Microbiol.* 2009;7:555-67.
46. Davies JE. Origins, acquisition and dissemination of antibiotic resistance determinants. *Ciba Found Symp.* 1997;207:15-27, discussion 27-35.
47. Martínez JL, Baquero F, Andersson DI. Predicting antibiotic resistance. *Nat Rev Microbiol.* 2007;5:958-65.
48. Andersson DI, Hughes D. Antibiotic resistance and its cost: is it possible to reverse resistance? *Nat Rev Microbiol.* 2010;8:260-71.
49. Livermore D. Can better prescribing turn the tide of resistance? *Nat Rev Microbiol.* 2004;2:73-8.
50. Baek JY, Chung DR, Ko KS, et al. Genetic alterations responsible for reduced susceptibility to vancomycin in community-associated MRSA strains of ST72. *J Antimicrob Chemother.* 2017;72:2454-60.